Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and efficacy of GT801 Injection in adults with relapsed/refractory CD19-positive B-cell hematologic malignancies …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• GT801 Injection

Snippet

Sponsor: Grit Biotechnology | Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL) | EARLY_Phase 1 | Status: RECRUITING